The IsoCode Chip (SCBC) system captures the omic, or full, end function from thousands of single cells in parallel to better understand complex patient response. The system, recognized in the literature as the SCBC, has been well validated in various immune and cancer detection applications. For proteomic applications, it uses rigorous quantitation of ELISA antibody based capture, applied to single cell detection. Control of strict specificity, sensitivity, and variability provides the ability to compare across large groups of patients.
Mapping each cell's full function reveals powerful cell subsets. The IsoCode system uses its ability to detect full, omic function per cell to find subsets of cells that help determine objective patient response.
See Cancer Discovery for applying IsoCode Chip (SCBC) single-cell secretomic cytokine profiling to earlier understanding of cell immunotherapy patient responses.
Discover the benefits of Precision Profiling™ with IsoLight. The first and only system designed to discover new information in immunotherapy, including CAR-T and TCR-T product characterization, clinical biomarker discovery, and patient monitoring, and biomarkers for checkpoint-inhibitor and combination therapies.
The IsoLight is a versatile, precision engineering platform designed to understand and characterize differences among single cells, mapping thousands of cells per sample, to reveal full functional profiles and polyfunctionality among cell subsets to determine patient response and product quality.
Running the patented consumable IsoCode Chip (SCBC), the IsoLight benchtop system captures single-cell, secretomic, cytokine profiles from thousands of single cells in parallel to better understand complex immunotherapy patient response.
secretomics: TCR T-Cell and CAR T-Cell immuno-therapy personalized medicine
phosphoproteomics: improving predictive profiling of solid tumor glioblastoma
metabolomics: monitoring energy transfer and consumption in cancer for new biomarkers
secretomics: uncovering patient biomarkers in inflammatory cancers (myelofibrosis)